Editas Medicine saw the highest growth of 2.49% in patent filings and 1.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 2.49% and grants by 1.99%. GlobalData’s DataBook provides a comprehensive analysis of Editas Medicine’s patent filings and grants. Buy the databook here.
Smarter leaders trust GlobalData
Editas Medicine has been focused on protecting inventions in United States(US) with nine publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 41% filings and 50% grants. The United States(US), European Patent Office(EPO), World Intellectual Property Organization(WIPO), and Japan(JP) patent Office are among the top ten patent offices where Editas Medicine is filings its patents. Among the top granted patent authorities, Editas Medicine has 50% of its grants in United States(US), 25% in European Patent Office(EPO) and 25% in Israel(IL).
Regeneron Pharmaceuticals could be the strongest competitor for Editas Medicine
In terms of grant share, Editas Medicine stands in ninth position among its competitors. Regeneron Pharmaceuticals and Editas Medicine secured the top positions according to recent patent publication data.
Patents related to genomics and rare diseases lead Editas Medicine's portfolio
Editas Medicine has the highest number of patents in genomics followed by, rare diseases and cell & gene therapy. For genomics, nearly 67% of patents were filed and 33% of patents were granted in Q2 2024.
Hemoglobinopathies related patents lead Editas Medicine portfolio followed by pain, and sickle cell disease
Editas Medicine has highest number of patents in hemoglobinopathies followed by pain, sickle cell disease, human papillomavirus infections, and leber congenital amaurosis (lca). For hemoglobinopathies, nearly 40% of patents were filed and 67% of patents were granted in Q2 2024.
For comprehensive analysis of Editas Medicine's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.
Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.
